A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Tanguy Y SeiwertSara E KochannyKevin WoodFrancis P WordenDouglas R AdkinsJames L WadeBethany G SleckmanDaniel AndersonRyan J BrissonTheodore KarrisonWalter M StadlerEverett E VokesPublished in: Cancer (2020)
The study did not meet its primary endpoint of improvement in PFS. However, TC induced responses in cetuximab-refractory patients with good tolerability. The post hoc observation of activity in patients with acquired resistance (after prior benefit from cetuximab monotherapy) may warrant further investigation.